Fresenius Kabi Usa Drug Patent Portfolio
Fresenius Kabi Usa owns 11 orange book drugs protected by 36 US patents with Acetaminophen having the least patent protection, holding only 1 patent. And Diprivan with maximum patent protection, holding 10 patents. Given below is the list of Fresenius Kabi Usa's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10398669 | Levothyroxine liquid formulations | 01 Dec, 2036 | Active |
| US11135190 | Levothyroxine liquid formulations | 01 Dec, 2036 | Active |
| US9782376 | Levothyroxine liquid formulations | 01 Dec, 2036 | Active |
| US9271990 | Fulvestrant formulations | 17 May, 2034 | Active |
| US9248229 | Packaging system for oxygen-sensitive drugs | 12 Mar, 2034 | Active |
| US9072781 | Morphine formulations | 12 Mar, 2034 | Active |
| US9192608 | Morphine formulations | 12 Mar, 2034 | Active |
| US10188663 | Fulvestrant formulations | 14 Feb, 2034 | Active |
| US9833459 | Fulvestrant formulations | 14 Feb, 2034 | Active |
| US9636407 | Caspofungin acetate formulations | 21 Dec, 2032 | Active |
| US8962572 | Bortezomib formulations | 03 Nov, 2032 | Active |
| US9006289 | Levothyroxine formulations | 03 Oct, 2032 | Active |
| US9168238 | Levothyroxine formulations | 29 Aug, 2032 | Active |
| US9168239 | Levothyroxine formulations | 29 Aug, 2032 | Active |
| US9731082 | Drug container | 23 Apr, 2032 | Active |
| US8741959 | Paracetamol for parenteral administration | 19 Apr, 2030 | Active |
| US7857802 | Connector for medical liquid-containing packages and medical liquid-containing packages | 28 Nov, 2026 | Active |
| US7828787 | Connector for packaging containing medical fluids and packaging for medical fluids | 18 Oct, 2025 | Active |
| US9566260 | Treatment and prevention of liver disease associated with parenteral nutrition (PN) | 11 Jul, 2025 | Active |
| US9629821 | Treatment and prevention of liver disease associated with parenteral nutrition (PN) | 11 Jul, 2025 | Active |
| US8476010 | Propofol formulations with non-reactive container closures | 01 Jun, 2025 | Active |
| US8476010 | Propofol formulations with non-reactive container closures | 01 Dec, 2024 | Active |
| US10350186 | Treatment and prevention of liver disease associated with parenteral nutrition (PN) | 05 Nov, 2024 | Active |
| US8162915 | Connector for packings containing medical liquids, and corresponding packing for medical liquids | 23 May, 2024 | Expired |
| US8118802 | Connector for packaging containing medical fluids and packaging for medical fluids | 18 May, 2023 | Expired |
| US6589960 | Hydromorphone and hydrocodone compositions and methods for their synthesis | 09 Nov, 2020 | Expired |
| US5714520 | Propofol compostion containing edetate | 22 Sep, 2015 | Expired |
| US5731355 | Pharmaceutical compositions of propofol and edetate | 22 Sep, 2015 | Expired |
| US5731356 | Pharmaceutical compositions of propofol and edetate | 22 Sep, 2015 | Expired |
| US5908869 | Propofol compositions containing edetate | 22 Sep, 2015 | Expired |
| US5714520 | Propofol compostion containing edetate | 22 Mar, 2015 | Expired |
| US5731355 | Pharmaceutical compositions of propofol and edetate | 22 Mar, 2015 | Expired |
| US5731356 | Pharmaceutical compositions of propofol and edetate | 22 Mar, 2015 | Expired |
| US5908869 | Propofol compositions containing edetate | 22 Mar, 2015 | Expired |
| US5670524 | Methods and compositions for the treatment of pain utilizing ropivacaine | 23 Sep, 2014 | Expired |
| US5834489 | Methods and compositions for the treatment of pain utilizing ropivacaine | 26 May, 2014 | Expired |
Latest Legal Activities on Fresenius Kabi Usa's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Fresenius Kabi Usa.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 27 May, 2024 | US8162915 (Litigated) |
|
Expire Patent
Critical
| 25 Mar, 2024 | US8118802 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 11 Dec, 2023 | US8162915 (Litigated) |
| transaction for FDA Determination of Regulatory Review Period | 01 Nov, 2023 | US9566260 |
| transaction for FDA Determination of Regulatory Review Period | 19 Oct, 2023 | US9566260 |
|
Maintenance Fee Reminder Mailed
Critical
| 09 Oct, 2023 | US8118802 (Litigated) |
| Recordation of Patent eGrant | 12 Sep, 2023 | US11752164 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 12 Sep, 2023 | US11752164 |
| Mail Patent eGrant Notification | 12 Sep, 2023 | US11752164 |
|
Email Notification
Critical
| 12 Sep, 2023 | US11752164 |
| Patent eGrant Notification | 12 Sep, 2023 | US11752164 |
|
Recordation of Patent Grant Mailed
Critical
| 12 Sep, 2023 | US11752164 |
|
Email Notification
Critical
| 24 Aug, 2023 | US11752164 |
|
Issue Notification Mailed
Critical
| 23 Aug, 2023 | US11752164 |
|
Electronic Review
Critical
| 10 Aug, 2023 | US11752164 |
Fresenius Kabi Usa's Drug Patent Litigations
Fresenius Kabi Usa's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Feb 06, 2015, against patent number US8476010. The petitioner Dr. Reddy's Laboratories, Inc., challenged the validity of this patent, with Fresenius Kabi USA, LLC as the respondent. Click below to track the latest information on how companies are challenging Fresenius Kabi Usa's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8476010 | November, 2015 |
FWD Entered
(07 Jun, 2017)
| Fresenius Kabi USA, LLC | J Kyle Bass |
| US9006289 | January, 2017 |
Terminated-Settled
(19 Apr, 2017)
| Fresenius Kabi USA, LLC | Mylan Institutional Inc. |
| US9168238 | January, 2017 |
Terminated-Settled
(19 Apr, 2017)
| Fresenius Kabi USA, LLC | Mylan Institutional Inc. |
| US9168239 | January, 2017 |
Terminated-Settled
(19 Apr, 2017)
| Fresenius Kabi USA LLC | Mylan Institutional Inc. |
| US9566260 | March, 2014 |
Decision
(20 May, 2016)
| Mark Puder et al | |
| US8476010 | February, 2015 |
Terminated-Denied
(02 Apr, 2015)
| Fresenius Kabi USA, LLC | Dr. Reddy's Laboratories, Inc. |
Fresenius Kabi Usa Drug Patents' Oppositions Filed in EPO
Fresenius Kabi Usa drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 19, 2013, by Wibbelmann, Jobst. This opposition was filed on patent number EP10714862A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP10714862A | Dec, 2013 | Wibbelmann, Jobst | Opposition rejected |
Fresenius Kabi Usa's Family Patents
Fresenius Kabi Usa Drug List
Given below is the complete list of Fresenius Kabi Usa's drugs and the patents protecting them.
1. Acetaminophen
Acetaminophen is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8741959 | Paracetamol for parenteral administration |
19 Apr, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Acetaminophen's drug page
2. Bortezomib
Bortezomib is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8962572 | Bortezomib formulations |
03 Nov, 2032
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bortezomib's drug page
3. Caspofungin Acetate
Caspofungin Acetate is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9636407 | Caspofungin acetate formulations |
21 Dec, 2032
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Caspofungin Acetate's drug page
4. Dilaudid
Dilaudid is protected by 3 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9248229 | Packaging system for oxygen-sensitive drugs |
12 Mar, 2034
(9 years from now)
| Active |
| US9731082 | Drug container |
23 Apr, 2032
(7 years from now)
| Active |
| US6589960 | Hydromorphone and hydrocodone compositions and methods for their synthesis |
09 Nov, 2020
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dilaudid's drug page
5. Dilaudid-hp
Dilaudid-hp is protected by 3 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9248229 | Packaging system for oxygen-sensitive drugs |
12 Mar, 2034
(9 years from now)
| Active |
| US9731082 | Drug container |
23 Apr, 2032
(7 years from now)
| Active |
| US6589960 | Hydromorphone and hydrocodone compositions and methods for their synthesis |
09 Nov, 2020
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dilaudid-hp's drug page
Explore Our Curated Drug Screens
6. Diprivan
Diprivan is protected by 10 patents, out of which 8 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8476010
(Pediatric)
| Propofol formulations with non-reactive container closures |
01 Jun, 2025
(7 months from now)
| Active |
| US8476010 | Propofol formulations with non-reactive container closures |
01 Dec, 2024
(a month from now)
| Active |
| US5714520
(Pediatric)
| Propofol compostion containing edetate |
22 Sep, 2015
(9 years ago)
| Expired |
| US5731355
(Pediatric)
| Pharmaceutical compositions of propofol and edetate |
22 Sep, 2015
(9 years ago)
| Expired |
| US5731356
(Pediatric)
| Pharmaceutical compositions of propofol and edetate |
22 Sep, 2015
(9 years ago)
| Expired |
| US5908869
(Pediatric)
| Propofol compositions containing edetate |
22 Sep, 2015
(9 years ago)
| Expired |
| US5714520 | Propofol compostion containing edetate |
22 Mar, 2015
(9 years ago)
| Expired |
| US5731355 | Pharmaceutical compositions of propofol and edetate |
22 Mar, 2015
(9 years ago)
| Expired |
| US5731356 | Pharmaceutical compositions of propofol and edetate |
22 Mar, 2015
(9 years ago)
| Expired |
| US5908869 | Propofol compositions containing edetate |
22 Mar, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Diprivan's drug page
7. Fulvestrant
Fulvestrant is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9271990 | Fulvestrant formulations |
17 May, 2034
(9 years from now)
| Active |
| US10188663 | Fulvestrant formulations |
14 Feb, 2034
(9 years from now)
| Active |
| US9833459 | Fulvestrant formulations |
14 Feb, 2034
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fulvestrant's drug page
8. Levothyroxine Sodium
Levothyroxine Sodium is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10398669 | Levothyroxine liquid formulations |
01 Dec, 2036
(12 years from now)
| Active |
| US11135190 | Levothyroxine liquid formulations |
01 Dec, 2036
(12 years from now)
| Active |
| US9782376 | Levothyroxine liquid formulations |
01 Dec, 2036
(12 years from now)
| Active |
| US9006289 | Levothyroxine formulations |
03 Oct, 2032
(7 years from now)
| Active |
| US9168238 | Levothyroxine formulations |
29 Aug, 2032
(7 years from now)
| Active |
| US9168239 | Levothyroxine formulations |
29 Aug, 2032
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Levothyroxine Sodium's drug page
9. Morphine Sulfate
Morphine Sulfate is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9072781 | Morphine formulations |
12 Mar, 2034
(9 years from now)
| Active |
| US9192608 | Morphine formulations |
12 Mar, 2034
(9 years from now)
| Active |
| US9248229 | Packaging system for oxygen-sensitive drugs |
12 Mar, 2034
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Morphine Sulfate's drug page
10. Naropin
Naropin is protected by 6 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7857802 | Connector for medical liquid-containing packages and medical liquid-containing packages |
28 Nov, 2026
(2 years from now)
| Active |
| US7828787 | Connector for packaging containing medical fluids and packaging for medical fluids |
18 Oct, 2025
(1 year, 1 day from now)
| Active |
| US8162915 | Connector for packings containing medical liquids, and corresponding packing for medical liquids |
23 May, 2024
(4 months ago)
| Expired |
| US8118802 | Connector for packaging containing medical fluids and packaging for medical fluids |
18 May, 2023
(1 year, 4 months ago)
| Expired |
| US5670524 | Methods and compositions for the treatment of pain utilizing ropivacaine |
23 Sep, 2014
(10 years ago)
| Expired |
| US5834489 | Methods and compositions for the treatment of pain utilizing ropivacaine |
26 May, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Naropin's drug page
11. Omegaven
Omegaven is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9566260 | Treatment and prevention of liver disease associated with parenteral nutrition (PN) |
11 Jul, 2025
(8 months from now)
| Active |
| US9629821 | Treatment and prevention of liver disease associated with parenteral nutrition (PN) |
11 Jul, 2025
(8 months from now)
| Active |
| US10350186 | Treatment and prevention of liver disease associated with parenteral nutrition (PN) |
05 Nov, 2024
(19 days from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Omegaven's drug page